A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

Excluded: BRAF V600 mutation

For colorectal cancer: Patient has been diagnosed with histologically or cytologically proven BRAF-V600 positive CRC.

Must have received: standard of care therapy — all lines considered SOC for the patient's indication according to guidelines and local practice

Patient has received all lines of therapy that are considered SOC for the patient's indication according to applicable European/national professional society medical guidelines and local medical practice at time of enrollment ... led to insufficient response or were medically not justified or refused by the patient.

Cannot have received: systemic cancer treatment

Patient received last previous systemic cancer treatment (including anti-testosterone treatment) within less than 4 weeks prior enrollment.

Cannot have received: palliative radiotherapy

Exception: where RECIST 1.1 evaluable metastases are within the radiation area

Patient received last palliative radiotherapy within less than 4 weeks prior enrollment - where RECIST 1.1 evaluable metastases are within the radiation area.

Cannot have received: minor surgery

Patient received minor surgery (as judged by the investigator, i.e., port implantation) within less than 3 weeks prior enrollment.

Cannot have received: investigational research products

Patient participates in any other interventional clinical trial or has been treated with any investigational research products within 4 weeks prior to the initiation of screening.